Merck KGgA venture arm bets on 'next generation' cancer therapeutics player

M Ventures, the strategic, corporate venture capital arm of Merck KGgA, continues to fund iOmx Therapeutics AG, a company developing cancer therapeutics based on next generation immune checkpoint targets.

Related Keywords

Germany ,Wellington ,New Zealand General ,New Zealand ,German ,Philipp Beckhove ,Nisit Khandelwal ,German Cancer Research Centre ,Athos Service Gmb ,Athos Service Gmbh ,Besidesm Ventures ,Wellington Partners ,Bio Developments ,Pipelines ,Checkpoint Inhibitor ,Merck Kgaa ,Mmunotherapies ,